Andreas Fotopoulos

Andreas Fotopoulos


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
VZVASILIKI ZOI
VASILIKI ZOI
MGMaria Giannakopoulou
Maria Giannakopoulou
George A. AlexiouGeorge A. Alexiou
George A. Alexiou
PGPenelope Greece
Penelope Greece
STSAVVAS THALASSELIS
SAVVAS THALASSELIS
Chrissa SiokaChrissa Sioka
Chrissa Sioka
Cancer theragnostics is a novel approach that combines diagnostic imaging and radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized for positron emission tomography imaging through linkage to a proper radionuclide, and the other bearing an alpha- or beta-emitter isotope that can induce significant damage to cancer cells. In recent years, the use of theragnostics in nuclear medicine clinical practice has increased considerably, and thus investigation has focused on the identification of novel radionuclides that can bind to molecular targets that are typically dysregulated in different cancers. The major advantages of the theragnostic approach include the elimination of multi-step procedures, reduced adverse effects to normal tissues, early diagnosis, better predictive responses, and personalized patient care. This review aims to discuss emerging theragnostic molecules that have been investigated in a series of human malignancies, including gliomas, thyroid cancer, neuroendocrine tumors, cholangiocarcinoma, and prostate cancer, as well as potent and recently introduced molecular targets, like cell-surface receptors, kinases, and cell adhesion proteins. Furthermore, special reference has been made to copper radionuclides as theragnostic agents and their radiopharmaceutical applications since they present promising alternatives to the well-studied gallium-68 and lutetium-177.

10 November 2014 in International Journal of Molecular Imaging
Verified
Journal Article
Open access
PDF file
GAGeorge A. Alexiou
George A. Alexiou
XXXanthi Xourgia
Xanthi Xourgia
EVEvrysthenis Vartholomatos
Evrysthenis Vartholomatos
STSpyridon Tsiouris
Spyridon Tsiouris
JKJohn A. Kalef-Ezra
John A. Kalef-Ezra
AKAthanasios P. Kyritsis
Athanasios P. Kyritsis
Tc-Tetrofosmin (Tc-TF) and Tc-Sestamibi (Tc-MIBI) are SPECT tracers that have been used for brain tumor imaging. Tumor’s multidrug resistance phenotype, namely, P-glycoprotein (p-gp), and the multidrug resistance related proteins (MRPs) expression have been suggested to influence both tracers’ uptake. In the present study we set out to compare Tc-MIBI uptake in high-grade glioma cell lines and to investigate the influence of gliomas p-gp expression on both tracers’ uptake. We used four glioma cell lines (U251MG, A172, U87MG, and T98G). The expression of p-gp protein was evaluated by flow cytometry. Twenty μCi (7.4·105 Bq) of Tc-TF and Tc-MIBI were used. The radioactivity in the cellular lysate was measured with a dose calibrator. P-gp was significantly expressed only in the U251MG cell line (). In all gliomas cell lines (U251MG, U87MG, A172, and T98G) the Tc-TF uptake was significantly higher than Tc-sestamibi. The U251MG cell line, in which significant p-gp expression was documented, exhibited the strongest uptake difference. Tc-TF uptake was higher than Tc-MIBI in all studied high-grade glioma cell lines. Thus, Tc-TF may be superior to Tc-MIBI for glioma imaging in vivo.

12 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
VZVASILIKI ZOI
VASILIKI ZOI
MGMaria Giannakopoulou
Maria Giannakopoulou
George A. AlexiouGeorge A. Alexiou
George A. Alexiou
PGPenelope Greece
Penelope Greece
STSAVVAS THALASSELIS
SAVVAS THALASSELIS
Chrissa SiokaChrissa Sioka
Chrissa Sioka
Cancer theragnostics is a novel approach that combines diagnostic imaging and radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized for positron emission tomography imaging, through linkage to a proper radionuclide, and the other bearing a beta-emitter isotope that can induce significant damage to cancer cells. In recent years, the use of theragnostics in nuclear medicine clinical practice has increased considerably, and thus investigation has focused on the identification of novel radionuclides that can bind to molecular targets which are typically dysregulated in different cancers. The major advantages of the theragnostic approach include elimination of multi-step procedures, reduced adverse effects to normal tissues, early diagnosis, better predicting responses and personalized patient care. This review aims to discuss emerging theragnostic molecules that have been investigated in a series of human malignancies, including gliomas, thyroid cancer, neuroendocrine tumors, cholangiocarcinoma and prostate cancer, as well as potent and recently introduced molecular targets, like cell-surface receptors, kinases, and cell adhesion proteins. Furthermore, special reference has been made to copper radionuclides as theragnostic agents, and their radiopharmaceutical applications since they present promising alternatives to the well-studied gallium-68 and lutetium-177.

11 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SKStavroula Kyrkou
Stavroula Kyrkou
VBVasileios-Panagiotis Bistas
Vasileios-Panagiotis Bistas
Evangelia-Alexandra SalvanouEvangelia-Alexandra Salvanou
Evangelia-Alexandra Salvanou
TCTim R. Crook
Tim R. Crook
MGMaria Giannakopoulou
Maria Giannakopoulou
ATAndreas Tzakos
Andreas Tzakos
Glioblastoma, the most frequent malignant primary brain tumor in adults, presents a significant challenge in cancer treatment, with a mean survival of merely 12-15 months and a 5-year survival rate of less than 2%. Despite extensive research and current treatments, involving maximal surgical excision, radiation, and chemotherapy mainly with temozolomide (TMZ), recurrence remains nearly universal. This is attributable to its infiltrative nature and tumor cells may be found far from the surgical resection cav-ity. To address the critical need for improved diagnostic and therapeutic strategies for glioblastoma multiform (GBM), we have developed an innovative theranostic molecule, AGT-7, based on tetrofosmin, a compound used in nuclear medicine bioimaging, and TMZ. AGT-7 was specifically designed to enable simultaneous tumor imaging and tar-geted chemotherapy. Its diagnostic component was inspired by the ability of tetrofosmin to selectively accumulate in glioma mitochondria, driven by its positive charge and the negative membrane potential of these organelles. A chelating moiety allows for radio-labeling with technetium-99m (⁹⁹ᵐTc), enabling precise SPECT imaging. The therapeutic arm comprises a tethered TMZ moiety, delivering localized cytotoxic activity. In vitro studies demonstrated that AGT-7 exerts potent cytotoxic effects in GBM cell lines (T98 and U87), with superior therapeutic efficacy compared to TMZ alone. Toxicity assess-ment in zebrafish embryos confirmed a favorable safety profile. Furthermore, biodis-tribution studies in CFW mice showed that [⁹⁹ᵐTc]Tc-AGT-7 exhibited approximately tenfold lower heart uptake than [⁹⁹ᵐTc]Tc-tetrofosmin, a standard cardiac imaging agent, indicating a significant reduction in off-target cardiac localization. This reduced heart uptake is particularly advantageous, as it minimizes potential cardiotoxicity and en-hances the suitability of AGT-7 as a glioma-targeted theranostic agent.

8 August 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SKStavroula Kyrkou
Stavroula Kyrkou
VBVasileios-Panagiotis Bistas
Vasileios-Panagiotis Bistas
Evangelia-Alexandra SalvanouEvangelia-Alexandra Salvanou
Evangelia-Alexandra Salvanou
TCTim R. Crook
Tim R. Crook
MGMaria Giannakopoulou
Maria Giannakopoulou
ATAndreas Tzakos
Andreas Tzakos
Background: Glioblastoma, the most common malignant primary brain tumor in adults, continues to present a major therapeutic challenge, with a median survival of only 12–15 months and a 5-year survival rate below 2%. Despite aggressive treatment—including maximal surgical excision, radiation, and temozolomide (TMZ) chemotherapy—recurrent disease is nearly universal due to the tumor’s infiltrative nature. Objectives: To address the critical need for improved diagnostic and therapeutic strategies for glioblastoma multiforme (GBM), we have developed an innovative theranostic molecule, [99mTc]Tc-AGT-7. Methods: AGT-7 integrates diagnostic and therapeutic modalities comprising [99mTc]Tc-TF (a nuclear medicine imaging agent) and TMZ. The diagnostic component has been tailored to selectively accumulate in glioma mitochondria. A chelating moiety enables radiolabeling with technetium-99m (99mTc) for precise Single-Photon Emission Computed Tomography (SPECT) imaging. The therapeutic arm includes the tethering of a TMZ moiety for localized cytotoxicity. Conclusions: In vitro studies illustrated that AGT-7 has potent cytotoxic effects in GBM cell lines (T98 and U87), with greater efficacy than TMZ, and toxicity assays in zebrafish embryos indicated a favorable safety profile. Biodistribution studies in CFW mice demonstrated that [99mTc]Tc-AGT-7 exhibited a ~10-fold lower heart uptake compared to [99mTc]Tc-TF, implying reduced off-target cardiac localization. This significantly lowers the risk of cardiotoxicity and enhances AGT-7’s potential as a glioma-targeted theranostic agent.